Dexamfetamine transdermal - Noven Pharmaceuticals

Drug Profile

Dexamfetamine transdermal - Noven Pharmaceuticals

Alternative Names: ATS; d-Amphetamine Transdermal System; d-ATS; Dextroamphetamine transdermal system - Noven; SPD-487

Latest Information Update: 03 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noven Pharmaceuticals
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder

Most Recent Events

  • 03 Aug 2015 Phase II development for Attention-deficit hyperactivity disorder is ongoing in the USA
  • 31 Mar 2013 Noven Pharmaceuticals completes a phase IIa trial in Attention-deficit hyperactivity disorder in USA (NCT01711021)
  • 02 Oct 2012 Phase-II clinical trials in Attention-deficit hyperactivity disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top